久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Basic Info

  • Grade: pharmaceutical grade

    Factory Location: Shanghai

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Lofitinib is an oral inhibitor of various kinases, including receptor tyrosine kinase asexual lymphoma kinase (ALK), c-ros tumor gene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK) types 1, 2, and 3, oncogene SRC, and focal adhesion kinase (FAK), with potential anti-tumor activity. After oral administration, rapatinib binds to wild-type, point mutants, and fusion proteins of ALK, ROS1, NTRK1-3, SRC, and FAK and inhibits them to a lesser extent, while inhibiting other kinases. Inhibiting these kinases can lead to the disruption of downstream signaling pathways and inhibit the cell growth of tumors with overexpression, rearrangement, or mutation of these kinases.
Send your message to this supplier
  • From:
  • To:
    Shanghai Hope-chem Co.,Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    -?Supports?jpg,?jpeg,?png,
    ?gif,?pdf,?doc,?docx,
    ?xls,?xlsx,?txt,?rar?and?zip
    -?Max?upload?3?files;
    ?Max??total?size:?3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service